In GBM and other tumor types, where the SHH pathway presents an important role for GSC maintenance, the targeting of SHH in combination with other drugs might be more suitable, as has been demonstrated in vitro and in vivo [159,160,161]. This evidence concerns the gene SHH and neoplasm.